Related Experiment Video
Updated: Aug 1, 2025
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
Published on: November 10, 2023
MCL-1 Inhibitor S63845 Distinctively Affects Intramedullary and Extramedullary Hematopoiesis
Hexiao Zhang1,2, Fei Li3, Ming Yang1,2
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, PUMC Department of Stem Cell and Regenerative Medicine, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
Abstract:
Conventional chemotherapy for killing cancer cells using cytotoxic drugs suffers from low selectivity, significant toxicity, and a narrow therapeutic index. Hyper-specific targeted drugs achieve precise destruction of tumors by inhibiting molecular pathways that are critical to tumor growth. Myeloid cell leukemia 1 (MCL-1), an important pro-survival protein in the BCL-2 family, is a promising antitumor target. In this study, we chose to investigate the effects of S63845, a small-molecule inhibitor that targets MCL-1, on the normal hematopoietic system. A mouse model of hematopoietic injury was constructed, and the effects of the inhibitor on the hematopoietic system of mice were evaluated via routine blood tests and flow cytometry. The results showed that S63845 affected the hematopoiesis of various lineages in the early stage of action, causing extramedullary compensatory hematopoiesis in the myeloid and megakaryocytic lineages. The maturation of the erythroid lineage in the intramedullary and extramedullary segments was blocked to varying degrees, and both the intramedullary and extramedullary lymphoid lineages were inhibited. This study provides a complete description of the effects of MCL-1 inhibitor on the intramedullary and extramedullary hematopoietic lineages, which is important for the selection of combinations of antitumor drugs and the prevention of adverse hematopoiesis-related effects.
Insights
The MCL-1 inhibitor S63845 impacts early hematopoiesis, causing compensatory extramedullary hematopoiesis and blocking erythroid maturation. This study details its effects on hematopoietic lineages, crucial for safe cancer drug combinations.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Conventional chemotherapy exhibits low selectivity and high toxicity.
- Targeted therapies offer precise tumor destruction by inhibiting critical molecular pathways.
- Myeloid cell leukemia 1 (MCL-1) is a pro-survival protein and a promising antitumor target.
Purpose of the Study:
- To investigate the effects of the MCL-1 inhibitor S63845 on the normal hematopoietic system.
- To evaluate the impact of S63845 on intramedullary and extramedullary hematopoietic lineages.
Main Methods:
- Construction of a mouse model of hematopoietic injury.
- Evaluation of S63845 effects using routine blood tests and flow cytometry.
Main Results:
- S63845 affected hematopoiesis across multiple lineages in early stages.
- Observed extramedullary compensatory hematopoiesis in myeloid and megakaryocytic lineages.
- Demonstrated blocked erythroid maturation and inhibited lymphoid lineages (intramedullary and extramedullary).
Conclusions:
- S63845 significantly impacts normal hematopoiesis, affecting various cell lineages.
- Findings are vital for selecting combination antitumor drugs and preventing adverse hematopoiesis-related effects.
- Provides a comprehensive analysis of MCL-1 inhibitor effects on hematopoietic lineages.
